Teva Pharmaceutical Industries Limited (TEVJF)
OTCMKTS · Delayed Price · Currency is USD
17.80
-1.51 (-7.82%)
At close: May 28, 2025
TEVJF Revenue
Teva Pharmaceutical Industries had revenue of $3.89B in the quarter ending March 31, 2025, with 1.89% growth. This brings the company's revenue in the last twelve months to $16.62B, up 3.82% year-over-year. In the year 2024, Teva Pharmaceutical Industries had annual revenue of $16.54B with 4.40% growth.
Revenue (ttm)
16.62B
Revenue Growth
+3.82%
P/S Ratio
1.11
Revenue / Employee
449.08K
Employees
35,686
Market Cap
18.36B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
Teva Pharmaceutical Industries News
- 20 days ago - Teva Releases Q2 2025 Aide Memoire - GlobeNewsWire
- 21 days ago - Viatris Eye Drops Data Shows Promise For Blurred Near Vision - Benzinga
- 21 days ago - Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility - Benzinga
- 21 days ago - Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025 - GlobeNewsWire
- 24 days ago - Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine - GlobeNewsWire
- 4 weeks ago - Teva and Fosun partner to develop TEV-56278 against cancers - Seeking Alpha
- 4 weeks ago - Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology - PRNewsWire
- 5 weeks ago - Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript - Seeking Alpha